SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person* Hartzel William (Last) (First) (Middle) 400 PROFESSIONAL DRIVE, STE. 400 (Street) GAITHERSBURG MD 20879 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 08/08/2023	3. Issuer Name and Ticker or Trading Symbol Emergent BioSolutions Inc. [ EBS ]
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) SVP, Bioservices	5. If Amendment, Date of Original Filed (Month/Day/Year)
			6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	35,917(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Options (Right to Buy)	(2)	04/07/2029	Common Stock	11,826	$42.28	D
Employee Stock Options (Right to Buy)	(3)	03/05/2030	Common Stock	3,077	$11.66	D
Employee Stock Options (Right to Buy)	(3)	06/08/2030	Common Stock	12,308	$8.39	D

Explanation of Responses:

1. Consists of 2,230 shares of common stock, including 800 shares purchased through the Company's Employee Share Purchase Program, and 25,994 unvested RSUs and 7,693 unvested PSUs granted from the Emergent Stock Incentive Plan. Each RSU and PSU represents a right to receive one share of common stock. The RSUs vest in three equal installments annually on the day prior to the anniversary date of the grant. The PSUs vest upon achievement with respect to both cumulative revenues and adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2023 and ending December 31, 2025, as certified by the Compensation Committee following the performance period. The amount reported is based on the target performance payout factor, or 100%.

2. This Employee Stock Option award is 1/3 vested and exercisable and 2/3 unvested as of the filing of this Form 3. The unvested Employee Stock Options vest in annual installments beginning on the day prior to the anniversary date of the grant.

3. Vests in three equal installments beginning on the day prior to the anniversary date of the grant.

Remarks:

Exhibit list: Ex 24.1 - Power of Attorney

	/s/ Jennifer Lynne Fox, Attorney-in-fact	08/15/2023
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.